Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. has released a special report detailing the deposit and actual use of proceeds for the first half of 2025. The report, in compliance with regulatory guidelines, outlines the company’s financial activities following its initial public offering of A shares in 2020, highlighting its adherence to regulatory standards and transparency in financial operations.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a Chinese joint stock company operating in the biopharmaceutical industry. It focuses on the research, development, and commercialization of innovative drugs, particularly in the field of oncology and autoimmune diseases.
Average Trading Volume: 13,773,473
Technical Sentiment Signal: Buy
Current Market Cap: HK$48.06B
Learn more about 1877 stock on TipRanks’ Stock Analysis page.